カテゴリー： Market Monitor Global, 世界, 医療/バイオ

核種医薬品のグローバル市場展望 2023年-2029年：テクネチウム-99、 ヨウ素-123、 ヨウ素-125、 ヨウ素-131、 フッ素-18、 ガリウム-67、 その他

◆英語タイトル：Nuclide Drugs Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが発行した調査報告書（MMG23DC16499）◆商品コード：MMG23DC16499
◆発行会社（リサーチ会社）：Market Monitor Global
◆発行日：2023年12月
◆ページ数：67
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
◆産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

当調査レポートは次の情報を含め、世界の核種医薬品市場規模と予測を収録しています。・世界の核種医薬品市場：売上、2018年-2023年、2024年-2029年
・世界の核種医薬品市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の核種医薬品市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「テクネチウム-99」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

核種医薬品のグローバル主要企業は、GE Healthcare、 Cardinal Health、 Curium Pharma、 Lantheus Medical Imaging, Inc.、 Eczacıbaşı Monrol Nuclear Products、 Novartis International AG、 Siemens、 China Isotope & Radiation、 Yantai Dongcheng Pharmaceutical、 Jubilant Life Sciences、 Braccoなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、核種医薬品のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の核種医薬品市場：タイプ別、2018年-2023年、2024年-2029年
世界の核種医薬品市場：タイプ別市場シェア、2022年
・テクネチウム-99、 ヨウ素-123、 ヨウ素-125、 ヨウ素-131、 フッ素-18、 ガリウム-67、 その他

世界の核種医薬品市場：用途別、2018年-2023年、2024年-2029年
世界の核種医薬品市場：用途別市場シェア、2022年
・治療用、診断用

世界の核種医薬品市場：地域・国別、2018年-2023年、2024年-2029年
世界の核種医薬品市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における核種医薬品のグローバル売上、2018年-2023年
・主要企業における核種医薬品のグローバル売上シェア、2022年
・主要企業における核種医薬品のグローバル販売量、2018年-2023年
・主要企業における核種医薬品のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
GE Healthcare、 Cardinal Health、 Curium Pharma、 Lantheus Medical Imaging, Inc.、 Eczacıbaşı Monrol Nuclear Products、 Novartis International AG、 Siemens、 China Isotope & Radiation、 Yantai Dongcheng Pharmaceutical、 Jubilant Life Sciences、 Bracco

*************************************************************

・調査・分析レポートの概要
核種医薬品市場の定義
市場セグメント
世界の核種医薬品市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の核種医薬品市場規模
世界の核種医薬品市場規模：2022年 VS 2029年
世界の核種医薬品市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの核種医薬品の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の核種医薬品製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：テクネチウム-99、 ヨウ素-123、 ヨウ素-125、 ヨウ素-131、 フッ素-18、 ガリウム-67、 その他
核種医薬品のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：治療用、診断用
核種医薬品の用途別グローバル売上・予測

・地域別市場分析
地域別核種医薬品市場規模 2022年と2029年
地域別核種医薬品売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
GE Healthcare、 Cardinal Health、 Curium Pharma、 Lantheus Medical Imaging, Inc.、 Eczacıbaşı Monrol Nuclear Products、 Novartis International AG、 Siemens、 China Isotope & Radiation、 Yantai Dongcheng Pharmaceutical、 Jubilant Life Sciences、 Bracco
...

This research report provides a comprehensive analysis of the Nuclide Drugs market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Nuclide Drugs market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Nuclide Drugs, challenges faced by the industry, and potential opportunities for market players.
The global Nuclide Drugs market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Nuclide Drugs market presents opportunities for various stakeholders, including Therapeutic Use, Diagnostic Use. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Nuclide Drugs market. Additionally, the growing consumer demand present avenues for market expansion.
The global Nuclide Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Key Features:
The research report on the Nuclide Drugs market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Nuclide Drugs market.
Market Overview: The report provides a comprehensive overview of the Nuclide Drugs market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Technetium-99, Iodine-123), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Nuclide Drugs market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Nuclide Drugs market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Nuclide Drugs market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Nuclide Drugs market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Nuclide Drugs market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Nuclide Drugs market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Nuclide Drugs, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Nuclide Drugs market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Nuclide Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Technetium-99
Iodine-123
Iodine-125
Iodine-131
Fluorine-18
Gallium-67
Others
Market segment by Application
Therapeutic Use
Diagnostic Use
Global Nuclide Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
GE Healthcare
Cardinal Health
Curium Pharma
Lantheus Medical Imaging, Inc.
Eczacıbaşı Monrol Nuclear Products
Novartis International AG
Siemens
China Isotope & Radiation
Yantai Dongcheng Pharmaceutical
Jubilant Life Sciences
Bracco
Outline of Major Chapters:
Chapter 1: Introduces the definition of Nuclide Drugs, market overview.
Chapter 2: Global Nuclide Drugs market size in revenue.
Chapter 3: Detailed analysis of Nuclide Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Nuclide Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Nuclide Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Nuclide Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Nuclide Drugs Overall Market Size
2.1 Global Nuclide Drugs Market Size: 2022 VS 2029
2.2 Global Nuclide Drugs Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Nuclide Drugs Players in Global Market
3.2 Top Global Nuclide Drugs Companies Ranked by Revenue
3.3 Global Nuclide Drugs Revenue by Companies
3.4 Top 3 and Top 5 Nuclide Drugs Companies in Global Market, by Revenue in 2022
3.5 Global Companies Nuclide Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Nuclide Drugs Players in Global Market
3.6.1 List of Global Tier 1 Nuclide Drugs Companies
3.6.2 List of Global Tier 2 and Tier 3 Nuclide Drugs Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Nuclide Drugs Market Size Markets, 2022 & 2029
4.1.2 Technetium-99
4.1.3 Iodine-123
4.1.4 Iodine-125
4.1.5 Iodine-131
4.1.6 Fluorine-18
4.1.7 Gallium-67
4.1.8 Others
4.2 By Type – Global Nuclide Drugs Revenue & Forecasts
4.2.1 By Type – Global Nuclide Drugs Revenue, 2018-2023
4.2.2 By Type – Global Nuclide Drugs Revenue, 2024-2029
4.2.3 By Type – Global Nuclide Drugs Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Nuclide Drugs Market Size, 2022 & 2029
5.1.2 Therapeutic Use
5.1.3 Diagnostic Use
5.2 By Application – Global Nuclide Drugs Revenue & Forecasts
5.2.1 By Application – Global Nuclide Drugs Revenue, 2018-2023
5.2.2 By Application – Global Nuclide Drugs Revenue, 2024-2029
5.2.3 By Application – Global Nuclide Drugs Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Nuclide Drugs Market Size, 2022 & 2029
6.2 By Region – Global Nuclide Drugs Revenue & Forecasts
6.2.1 By Region – Global Nuclide Drugs Revenue, 2018-2023
6.2.2 By Region – Global Nuclide Drugs Revenue, 2024-2029
6.2.3 By Region – Global Nuclide Drugs Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Nuclide Drugs Revenue, 2018-2029
6.3.2 US Nuclide Drugs Market Size, 2018-2029
6.3.3 Canada Nuclide Drugs Market Size, 2018-2029
6.3.4 Mexico Nuclide Drugs Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Nuclide Drugs Revenue, 2018-2029
6.4.2 Germany Nuclide Drugs Market Size, 2018-2029
6.4.3 France Nuclide Drugs Market Size, 2018-2029
6.4.4 U.K. Nuclide Drugs Market Size, 2018-2029
6.4.5 Italy Nuclide Drugs Market Size, 2018-2029
6.4.6 Russia Nuclide Drugs Market Size, 2018-2029
6.4.7 Nordic Countries Nuclide Drugs Market Size, 2018-2029
6.4.8 Benelux Nuclide Drugs Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Nuclide Drugs Revenue, 2018-2029
6.5.2 China Nuclide Drugs Market Size, 2018-2029
6.5.3 Japan Nuclide Drugs Market Size, 2018-2029
6.5.4 South Korea Nuclide Drugs Market Size, 2018-2029
6.5.5 Southeast Asia Nuclide Drugs Market Size, 2018-2029
6.5.6 India Nuclide Drugs Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Nuclide Drugs Revenue, 2018-2029
6.6.2 Brazil Nuclide Drugs Market Size, 2018-2029
6.6.3 Argentina Nuclide Drugs Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Nuclide Drugs Revenue, 2018-2029
6.7.2 Turkey Nuclide Drugs Market Size, 2018-2029
6.7.3 Israel Nuclide Drugs Market Size, 2018-2029
6.7.4 Saudi Arabia Nuclide Drugs Market Size, 2018-2029
6.7.5 UAE Nuclide Drugs Market Size, 2018-2029
7 Nuclide Drugs Companies Profiles
7.1 GE Healthcare
7.1.1 GE Healthcare Company Summary
7.1.2 GE Healthcare Business Overview
7.1.3 GE Healthcare Nuclide Drugs Major Product Offerings
7.1.4 GE Healthcare Nuclide Drugs Revenue in Global Market (2018-2023)
7.1.5 GE Healthcare Key News & Latest Developments
7.2 Cardinal Health
7.2.1 Cardinal Health Company Summary
7.2.2 Cardinal Health Business Overview
7.2.3 Cardinal Health Nuclide Drugs Major Product Offerings
7.2.4 Cardinal Health Nuclide Drugs Revenue in Global Market (2018-2023)
7.2.5 Cardinal Health Key News & Latest Developments
7.3 Curium Pharma
7.3.1 Curium Pharma Company Summary
7.3.2 Curium Pharma Business Overview
7.3.3 Curium Pharma Nuclide Drugs Major Product Offerings
7.3.4 Curium Pharma Nuclide Drugs Revenue in Global Market (2018-2023)
7.3.5 Curium Pharma Key News & Latest Developments
7.4 Lantheus Medical Imaging, Inc.
7.4.1 Lantheus Medical Imaging, Inc. Company Summary
7.4.2 Lantheus Medical Imaging, Inc. Business Overview
7.4.3 Lantheus Medical Imaging, Inc. Nuclide Drugs Major Product Offerings
7.4.4 Lantheus Medical Imaging, Inc. Nuclide Drugs Revenue in Global Market (2018-2023)
7.4.5 Lantheus Medical Imaging, Inc. Key News & Latest Developments
7.5 Eczacıbaşı Monrol Nuclear Products
7.5.1 Eczacıbaşı Monrol Nuclear Products Company Summary
7.5.2 Eczacıbaşı Monrol Nuclear Products Business Overview
7.5.3 Eczacıbaşı Monrol Nuclear Products Nuclide Drugs Major Product Offerings
7.5.4 Eczacıbaşı Monrol Nuclear Products Nuclide Drugs Revenue in Global Market (2018-2023)
7.5.5 Eczacıbaşı Monrol Nuclear Products Key News & Latest Developments
7.6 Novartis International AG
7.6.1 Novartis International AG Company Summary
7.6.2 Novartis International AG Business Overview
7.6.3 Novartis International AG Nuclide Drugs Major Product Offerings
7.6.4 Novartis International AG Nuclide Drugs Revenue in Global Market (2018-2023)
7.6.5 Novartis International AG Key News & Latest Developments
7.7 Siemens
7.7.1 Siemens Company Summary
7.7.2 Siemens Business Overview
7.7.3 Siemens Nuclide Drugs Major Product Offerings
7.7.4 Siemens Nuclide Drugs Revenue in Global Market (2018-2023)
7.7.5 Siemens Key News & Latest Developments
7.8 China Isotope & Radiation
7.8.1 China Isotope & Radiation Company Summary
7.8.2 China Isotope & Radiation Business Overview
7.8.3 China Isotope & Radiation Nuclide Drugs Major Product Offerings
7.8.4 China Isotope & Radiation Nuclide Drugs Revenue in Global Market (2018-2023)
7.8.5 China Isotope & Radiation Key News & Latest Developments
7.9 Yantai Dongcheng Pharmaceutical
7.9.1 Yantai Dongcheng Pharmaceutical Company Summary
7.9.2 Yantai Dongcheng Pharmaceutical Business Overview
7.9.3 Yantai Dongcheng Pharmaceutical Nuclide Drugs Major Product Offerings
7.9.4 Yantai Dongcheng Pharmaceutical Nuclide Drugs Revenue in Global Market (2018-2023)
7.9.5 Yantai Dongcheng Pharmaceutical Key News & Latest Developments
7.10 Jubilant Life Sciences
7.10.1 Jubilant Life Sciences Company Summary
7.10.2 Jubilant Life Sciences Business Overview
7.10.3 Jubilant Life Sciences Nuclide Drugs Major Product Offerings
7.10.4 Jubilant Life Sciences Nuclide Drugs Revenue in Global Market (2018-2023)
7.10.5 Jubilant Life Sciences Key News & Latest Developments
7.11 Bracco
7.11.1 Bracco Company Summary
7.11.2 Bracco Business Overview
7.11.3 Bracco Nuclide Drugs Major Product Offerings
7.11.4 Bracco Nuclide Drugs Revenue in Global Market (2018-2023)
7.11.5 Bracco Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. Nuclide Drugs Market Opportunities & Trends in Global Market
Table 2. Nuclide Drugs Market Drivers in Global Market
Table 3. Nuclide Drugs Market Restraints in Global Market
Table 4. Key Players of Nuclide Drugs in Global Market
Table 5. Top Nuclide Drugs Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Nuclide Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Nuclide Drugs Revenue Share by Companies, 2018-2023
Table 8. Global Companies Nuclide Drugs Product Type
Table 9. List of Global Tier 1 Nuclide Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Nuclide Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Nuclide Drugs Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Nuclide Drugs Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Nuclide Drugs Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global Nuclide Drugs Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Nuclide Drugs Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Nuclide Drugs Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global Nuclide Drugs Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Nuclide Drugs Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Nuclide Drugs Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Nuclide Drugs Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Nuclide Drugs Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Nuclide Drugs Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Nuclide Drugs Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Nuclide Drugs Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Nuclide Drugs Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Nuclide Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Nuclide Drugs Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Nuclide Drugs Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Nuclide Drugs Revenue, (US$, Mn), 2024-2029
Table 30. GE Healthcare Company Summary
Table 31. GE Healthcare Nuclide Drugs Product Offerings
Table 32. GE Healthcare Nuclide Drugs Revenue (US$, Mn) & (2018-2023)
Table 33. GE Healthcare Key News & Latest Developments
Table 34. Cardinal Health Company Summary
Table 35. Cardinal Health Nuclide Drugs Product Offerings
Table 36. Cardinal Health Nuclide Drugs Revenue (US$, Mn) & (2018-2023)
Table 37. Cardinal Health Key News & Latest Developments
Table 38. Curium Pharma Company Summary
Table 39. Curium Pharma Nuclide Drugs Product Offerings
Table 40. Curium Pharma Nuclide Drugs Revenue (US$, Mn) & (2018-2023)
Table 41. Curium Pharma Key News & Latest Developments
Table 42. Lantheus Medical Imaging, Inc. Company Summary
Table 43. Lantheus Medical Imaging, Inc. Nuclide Drugs Product Offerings
Table 44. Lantheus Medical Imaging, Inc. Nuclide Drugs Revenue (US$, Mn) & (2018-2023)
Table 45. Lantheus Medical Imaging, Inc. Key News & Latest Developments
Table 46. Eczacıbaşı Monrol Nuclear Products Company Summary
Table 47. Eczacıbaşı Monrol Nuclear Products Nuclide Drugs Product Offerings
Table 48. Eczacıbaşı Monrol Nuclear Products Nuclide Drugs Revenue (US$, Mn) & (2018-2023)
Table 49. Eczacıbaşı Monrol Nuclear Products Key News & Latest Developments
Table 50. Novartis International AG Company Summary
Table 51. Novartis International AG Nuclide Drugs Product Offerings
Table 52. Novartis International AG Nuclide Drugs Revenue (US$, Mn) & (2018-2023)
Table 53. Novartis International AG Key News & Latest Developments
Table 54. Siemens Company Summary
Table 55. Siemens Nuclide Drugs Product Offerings
Table 56. Siemens Nuclide Drugs Revenue (US$, Mn) & (2018-2023)
Table 57. Siemens Key News & Latest Developments
Table 58. China Isotope & Radiation Company Summary
Table 59. China Isotope & Radiation Nuclide Drugs Product Offerings
Table 60. China Isotope & Radiation Nuclide Drugs Revenue (US$, Mn) & (2018-2023)
Table 61. China Isotope & Radiation Key News & Latest Developments
Table 62. Yantai Dongcheng Pharmaceutical Company Summary
Table 63. Yantai Dongcheng Pharmaceutical Nuclide Drugs Product Offerings
Table 64. Yantai Dongcheng Pharmaceutical Nuclide Drugs Revenue (US$, Mn) & (2018-2023)
Table 65. Yantai Dongcheng Pharmaceutical Key News & Latest Developments
Table 66. Jubilant Life Sciences Company Summary
Table 67. Jubilant Life Sciences Nuclide Drugs Product Offerings
Table 68. Jubilant Life Sciences Nuclide Drugs Revenue (US$, Mn) & (2018-2023)
Table 69. Jubilant Life Sciences Key News & Latest Developments
Table 70. Bracco Company Summary
Table 71. Bracco Nuclide Drugs Product Offerings
Table 72. Bracco Nuclide Drugs Revenue (US$, Mn) & (2018-2023)
Table 73. Bracco Key News & Latest Developments
List of Figures
Figure 1. Nuclide Drugs Segment by Type in 2022
Figure 2. Nuclide Drugs Segment by Application in 2022
Figure 3. Global Nuclide Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Nuclide Drugs Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Nuclide Drugs Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Nuclide Drugs Revenue in 2022
Figure 8. By Type - Global Nuclide Drugs Revenue Market Share, 2018-2029
Figure 9. By Application - Global Nuclide Drugs Revenue Market Share, 2018-2029
Figure 10. By Type - Global Nuclide Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Nuclide Drugs Revenue Market Share, 2018-2029
Figure 12. By Application - Global Nuclide Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Nuclide Drugs Revenue Market Share, 2018-2029
Figure 14. By Region - Global Nuclide Drugs Revenue Market Share, 2018-2029
Figure 15. By Country - North America Nuclide Drugs Revenue Market Share, 2018-2029
Figure 16. US Nuclide Drugs Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Nuclide Drugs Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Nuclide Drugs Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Nuclide Drugs Revenue Market Share, 2018-2029
Figure 20. Germany Nuclide Drugs Revenue, (US$, Mn), 2018-2029
Figure 21. France Nuclide Drugs Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Nuclide Drugs Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Nuclide Drugs Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Nuclide Drugs Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Nuclide Drugs Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Nuclide Drugs Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Nuclide Drugs Revenue Market Share, 2018-2029
Figure 28. China Nuclide Drugs Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Nuclide Drugs Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Nuclide Drugs Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Nuclide Drugs Revenue, (US$, Mn), 2018-2029
Figure 32. India Nuclide Drugs Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Nuclide Drugs Revenue Market Share, 2018-2029
Figure 34. Brazil Nuclide Drugs Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Nuclide Drugs Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Nuclide Drugs Revenue Market Share, 2018-2029
Figure 37. Turkey Nuclide Drugs Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Nuclide Drugs Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Nuclide Drugs Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Nuclide Drugs Revenue, (US$, Mn), 2018-2029
Figure 41. GE Healthcare Nuclide Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Cardinal Health Nuclide Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Curium Pharma Nuclide Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Lantheus Medical Imaging, Inc. Nuclide Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Eczacıbaşı Monrol Nuclear Products Nuclide Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Novartis International AG Nuclide Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Siemens Nuclide Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. China Isotope & Radiation Nuclide Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Yantai Dongcheng Pharmaceutical Nuclide Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Jubilant Life Sciences Nuclide Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Bracco Nuclide Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 核種医薬品のグローバル市場展望 2023年-2029年：テクネチウム-99、 ヨウ素-123、 ヨウ素-125、 ヨウ素-131、 フッ素-18、 ガリウム-67、 その他(Nuclide Drugs Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 短時間作用型EPO医薬品のグローバル市場展望 2023年-2029年：エポエチンアルファ、エポエチンベータ、ダルベポエチンアルファ、その他
  • mRNAワクチン&mRNA医薬品のグローバル市場展望 2023年-2029年：ワクチン、原薬
  • 動物用医薬品のグローバル市場展望 2023年-2029年：肉フレーバー、魚フレーバー、フルーツフレーバー、その他
  • 心臓病学放射性医薬品のグローバル市場展望 2023年-2029年：テクネチウム-99、フッ素-18、ガリウム-67、その他
  • ウイルス性胃腸炎治療薬のグローバル市場展望 2023年-2029年：抗生物質、制酸剤、制吐剤、その他